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Issues to consider when a 
patient refuses treatment
By Laetitia Hattingh
Mrs A was diagnosed with cancer 
approximately four weeks ago and has 
started with chemotherapy prescribed 
by her oncologist. Today she presents 
with her prescriptions. She informs you 
that she only wants the pain medication 
and not her chemotherapy tablets as 
she has decided to discontinue her 
chemotherapy. She says that she has 
thought about this and has made up her 
mind as the side-effects are affecting 
her quality of life. She has done some 
research about the evidence of the 
treatment and weighed up the risks 
versus the benefits. She would rather 
use the time that she has left to spend 
some quality time with her children and 
grandchildren.
Patients have a right to refuse medical 
treatment which includes a right to refuse 
to take prescribed medicines. A patient’s 
refusal to receive treatment could cause 
a dilemma for health professionals. This is 
particularly complicated when the patient 
is very ill and the refusal to continue the 
intervention could cause the patient 
to become terminally ill. It is therefore 
important for health professionals to have 
an understanding of the law of consent 
and knowledge of the existing legal 
framework around refusal of treatment.
The right to refuse treatment
The right to refuse treatment is 
recognised in the common law that 
provides for a legally competent 
person to consent to treatment or to 
refuse treatment.1 This area of the law 
is an extension of the law of consent 
which recognises the autonomy of the 
individual. The common law principles 
of consent apply in that the decision 
to refuse treatment must be made 
voluntarily and the patient must be 
competent (an adult of sound mind).
The right to refuse treatment is also 
recognised in the Code of Conduct for 
Registered Health Practitioners2 stating 
that a good partnership between a 
practitioner and the person he/she is 
caring for involves ‘respecting the right of 
the patient or client to choose whether 
or not he or she participates in any 
treatment or accepts advice’. Principle 2 
and the supporting text of the Code of 
Ethics for Pharmacists3 states that:
‘A pharmacist pays due respect for the 
autonomy and rights of consumers 
and encourages consumers to actively 
participate in decision-making.’
‘A pharmacist will, through informed 
consent, pay due respect to the dignity 
and privacy of the consumer including: 
respecting the consumer’s individuality; 
respecting their right to refuse advice 
or treatment; and ensuring the privacy 
and confidentiality of the consumer and 
information provided’.
Pharmacists’ responsibilities
A pharmacist would need to consider 
his/her professional responsibility when 
a patient refuses to use prescribed 
medicine. The significance of the refusal 
will depend on the patient’s condition 
and the prescribed medicine. For 
example: a patient refusing to take an 
antibiotic might take longer to recover 
from an infection but would eventually 
still improve while the outcome could 
be quite different for a cancer patient 
refusing to use prescribed chemotherapy.
Pharmacists have a professional, ethical 
and legal responsibility to make sure 
that the refusal of treatment reflects the 
patient’s informed wishes or request and 
need to ensure that patients are informed 
about, and understand, the consequences 
of their refusal to receive treatment. 
It is therefore important to provide 
information in a way that the patient 
can understand and to document what 
information was provided and the advice 
that was given. 
It is also important to make sure that 
the patient has notified the treating 
medical practitioner(s) of the decision 
to cease the prescribed medicine(s). If 
the patient has not already notified the 
medical practitioner you could offer to 
facilitate this process. The situation will 
be complicated if the patient does not 
want to disclose their refusal to continue 
with the prescribed medicine to the 
treating medical practitioner. In this 
case the pharmacist will need to use his/
her professional judgement and weigh 
up patient confidentiality requirements 
against what is in the patient’s best 
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interest. Although patients have the right 
to confidentiality of their information 
there are certain exceptions to keeping 
patient information confidential. One 
such exception is where a range of 
health professionals are caring for a 
patient as there is implied consent to the 
communication of information necessary 
for the patient’s ongoing health care and 
wellbeing between those involved in the 
care. This exception could be used as a 
defence in the above situation although 
it would be wise to obtain a legal opinion 
before disclosing information.
Advance care planning and 
directives
It is worth mentioning that there are 
specific mechanisms in place in the 
various states and territories that cover 
advance care planning and directives 
for end-of-life care.4,5 These mechanisms 
allow patients to specify treatment of 
a future condition when the patient 
becomes legally incompetent. Advance 
care planning is achieved through the 
appointment of a substitute decision 
maker or the completion of an advanced 
directive, also referred to as a ‘living 
will’. These directives offer individuals a 
way of ensuring that their preferences 
about medical treatment and care will 
be acknowledged and respected in 
the future. 
Key points
Pharmacists will be challenged when 
patients refuse to take their prescribed 
medicines and/or receive medical 
treatment. It is therefore important to 
have an understanding of the law of 
consent and knowledge of the existing 
legal framework around refusal of 
treatment.
References
1. Forrester K, Griffiths D. Essentials of law for health professionals. 
Sydney: Mosby, Elsevier; 2010.
2. Pharmacy Board of Australia. Code of conduct for registered 
health practitioners. 2010; At: www.pharmacyboard.gov.au/
Codes-Guidelines.aspx 
3. Pharmaceutical Society of Australia. Code of Ethics for 
Pharmacists. 2011; 1–11. At: www.psa.org.au/supporting-
practice/legislation 
4. Medical Treatment Act 1988 (Vic), Natural Death Act 1988 (NT), 
Consent to Medical Treatment and Palliative Care Act 1995 (SA), 
Medical Treatment Act 1994 (ACT), Powers of Attorney Act 1998 
(Qld), Guardianship and Administration Act 1990 (WA).
5. NSW Health. Guidelines for end-of-life care and decision-
making. 2005.
The optimal loading dose  
of warfarin 
By Dr Hanan Khalil
Dr Hanan Khalil is the Director of the 
Centre for Chronic Disease Management, 
a collaborating centre of the Joanna 
Briggs Institute, Faculty of Medicine, 
Nursing and Health Sciences, Monash 
University, and a reviewer for the 
consumer group of the Cochrane 
Collaboration.
The purpose of this evidence summary is 
to provide the best available information 
on the optimal loading dose of warfarin 
for the initiation of anti-coagulation. For 
the full review, please refer to Mahtani 
KR, Heneghan CJ, Nunan D, et al. Optimal 
loading dose of warfarin for the initiation 
of oral anticoagulation. Cochrane Database 
of Systematic Reviews 2012, Issue 12. Art. 
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Background
Anticoagulants use has increased 
significantly over the past decade due to 
the ageing population. The benefits of 
anti-coagulants range from preventing 
and treating thrombotic events such as 
deep vein thrombosis (DVT), pulmonary 
embolism (PE) and heart valve replacement 
to managing atrial fibrillation (AF).2
Warfarin is a vitamin K antagonist that 
inhibits the activity of clotting factors II, 
VII and X. The dose of warfarin is variable, 
therefore monitoring therapy by using 
the International Normalised Ratio (INR) 
is recommended to ensure its safety and 
effective use.3
Selecting the right dose of warfarin to 
achieve the correct INR requires balancing 
the need for effective anticoagulation with 
reduced time to therapeutic INR without 
concomitant increases in adverse events.4 
The above mentioned review assesses 
the effectiveness in reaching a target INR 
from different loading dose regimens of 
warfarin in terms of time in-range, time to 
INR in-range and effect on serious adverse 
events.1
Characteristics of the studies
The studies selected for the systematic 
review were randomised controlled trials 
comparing various loading dose regimens 
in patients who are 18 years and older 
starting anti-coagulation with warfarin. 
Patients with conditions such as AF, DVT, PE, 
heart valve replacement and post-operative 
venous thromboembolism prophylaxis 
were included.
Quality of the research
All studies included in the report were 
either single or double blinded and were 
of moderate methodological quality. 
